| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2026: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2025: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2024: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2023: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Annual Research Achievements |
①てんかん重積についての臨床結果については、脳神経外科51巻6号に総説を報告した。（[Initial Management of Status Epilepticus].Inaji M, Maehara. No Shinkei Geka. 2023 Nov;51(6):1069-1077.）。
②側頭葉てんかんのネットワークについて、側頭葉てんかんにおけるMSTの効果について報告した。（Epilepsy surgery for dominant-side mesial temporal lobe epilepsy without hippocampal sclerosis.Abe D, Inaji M, Hashimoto S, Takagi S, Maehara T.J Clin Neurosci. 2023 May;111:16-21.）。また発作と不安症の関連について報告した（Seizure-related stress and arousal responses mediate a relationship between anxiety trait and state in epilepsy.Nakamura H, Sugihara G, Hara K, Inaji M, Noha M, Takumi I, Watanabe M, Takahashi H, Maehara T, Yamamoto H, Takagi S.Epilepsy Behav. 2023 Oct;147:109442. ）さらにはEcoGの技術的な問題について報告したClinical utility and safety of a trapezoid-shaped electrode placement for evaluating the mesio-basal temporal lobe during epilepsy surgery. Kaneko S, Inaji M, Shimizu K, Orihara A, Hashimoto Fujimoto S, Maehara T. J Clin Neurosci. 2024 Mar;121:28-33.）
②AMPA受容体に作用するPER効果について報告した。Long-term efficacy and safety of perampanel as an add-on therapy in patients with epilepsy.Arai Y, Inaji M, Shimizu K, Kondo S, Hashimoto-Fujimoto S, Kiyokawa J, Kawano Y, Yamamoto S, Maehara T.Epilepsy Res. 2024 Feb;200）
|
